ERLEADA® HAS BROAD ACCESS
for over 90% of Medicare Part D
80% of commercial patients*1
The information provided represents no statement, promise, or guarantee of Janssen Biotech, Inc., concerning levels of reimbursement, payment, or charge. Please consult your payer organization with regard to local or actual coverage, reimbursement policies, and determination processes. Information is subject to change without notice. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by any plan or insurer referenced herein. This communication is solely the responsibility of Janssen Biotech, Inc.
*Information is valid as of August 9, 2018, and is subject to change. Data as of August 9, 2018, includes Letter of Medical Necessity (LMN) and Interim Criteria.
1. Data on file. Janssen Biotech, Inc.